Bristol’s New Products Meet Early Launch Expectations
Even So, Currency Changes Lead To Lowered Revenue Guidance
Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.
